There are currently 1048 clinical trials in Portland, Oregon looking for participants to engage in research studies. Trials are conducted at various facilities, including Oregon Health & Science University, Oregon Health and Science University /ID# 216891, Providence Portland Medical Center and Providence Saint Vincent Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
NCT05902962
Recruiting
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Oregon Health and Science University - Casey Eye Institute, Portland, Oregon
Conditions: Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
Register for Updates
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases
NCT03870750
Recruiting
This phase II/III trial studies the best approach in improving quality of life and survival after a donor stem cell transplant in older, weak, or frail patients with blood diseases. Patients who have undergone a transplant often experience increases in disease and death. One approach, supportive and palliative care (SPC), focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects. While a second approach... Read More
Gender:
All
Ages:
20 years and above
Trial Updated:
05/30/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Non-Neoplastic Hematologic and Lymphocytic Disorder
Register for Updates
Health Disparities in Prevalence of Hypertension Between Black and White Americans
NCT03558893
Recruiting
This study will be the first to distinguish the relative contributions of sleep, circadian and behavioral mechanisms to the non-dipping BP profile in Black adults and will lay the groundwork for optimizing therapies dependent on mechanisms, such as targeting sleep, targeting circadian rhythmicity, or targeting behaviors, and raising the possibility that ideal therapy for hypertension (HTN) may differ by race. This research will ultimately help to improve health and survival in black populations... Read More
Gender:
All
Ages:
Between 40 years and 60 years
Trial Updated:
05/30/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Hypertension, Cardiovascular Risk Factor
Register for Updates
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
NCT05957367
Recruiting
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of DCC-3116 with other anticancer agents.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: GIST
Register for Updates
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
NCT05573984
Recruiting
The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.
Gender:
All
Ages:
10 years and above
Trial Updated:
05/30/2024
Locations: Oregon Health and Science University - Casey Eye Institute, Portland, Oregon
Conditions: Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive
Register for Updates
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
NCT06042920
Recruiting
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: Local Institution - 0021, Portland, Oregon
Conditions: Palmoplantar Psoriasis, Genital Psoriasis
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: Providence Cancer Institute - Oncology Clinical Trials, Portland, Oregon
Conditions: Triple Negative Breast Cancer
Register for Updates
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628
Recruiting
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
05/29/2024
Locations: Legacy Emanuel Children's Hospital, Portland, Oregon +1 locations
Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Register for Updates
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
NCT05702645
Recruiting
This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear of their risk for long-term effects of cancer treatment. By learning more about the factors that may contribute to chronic health conditions and long-term effects after treatment for leukemia in persons with Down syndrome, clinical practice guidelines for survi... Read More
Gender:
All
Ages:
Between 6 years and 39 years
Trial Updated:
05/29/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Down Syndrome, B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
Register for Updates
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
NCT03467958
Recruiting
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2024
Locations: Local Institution - 113, Portland, Oregon
Conditions: Crohn Disease
Register for Updates
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
NCT05819359
Recruiting
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
05/29/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Parkinson's Disease
Register for Updates
BPL-003 Efficacy and Safety in Treatment Resistant Depression
NCT05870540
Recruiting
This is a Phase 2 study randomized, quadruple masked, multi-center study designed to investigate the efficacy and safety of a single dose of BPL-003 combined with psychological support in patients with treatment resistant depression (TRD).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2024
Locations: Portland Psychotherapy, Portland, Oregon
Conditions: Treatment Resistant Depression
Register for Updates